Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

October 31, 2021

Conditions
Pregnancy RelatedCOVIDCovid-19
Interventions
DRUG

Hydroxychloroquine

Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).

DRUG

Placebo

Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.

Trial Locations (9)

28031

Hospital Universitario Infanta Leonor, Madrid

28850

Hospital Universitario de Torrejón, Torrejón de Ardoz

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

28938

HM Puerta del Sur, Móstoles

40002

Hospital General de Segovia, Segovia

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08041

Hospital de la Sant Creu i Sant Pau, Barcelona

08950

Hospital Sant Joan de Déu, Esplugues de Llobregat

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

collaborator

University Hospital of Torrejon

OTHER

collaborator

Fundación de investigación HM

OTHER

collaborator

Hospital Sant Joan de Deu

OTHER

collaborator

Hospital del Mar

OTHER

collaborator

Hospital Universitario Infanta Leonor

OTHER

collaborator

Hospital Universitario Fundación Alcorcón

OTHER

collaborator

Hospital General de Segovia

OTHER

collaborator

Institut Català de la Salut

OTHER

lead

Barcelona Institute for Global Health

OTHER

NCT04410562 - Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum | Biotech Hunter | Biotech Hunter